Monitor for updates on the strategic process involving ART100 monetization; this order provides validation and could enhance deal terms. The reference from NYU Langone may attract additional hospital customers or acquirers.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · May 18 $0.3723entry
- T+1 · 6mo ago +2.07%α +2.72% · $0.3800
- T+5 · 6mo ago +308.27%α +306.65% · $1.52
- T+20 · 5mo ago +245.15%α +243.57% · $1.29
- T+60 · due 3mo ago Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Inspira Technologies received a $580,000 commercial purchase order from NYU Langone Hospital for its FDA-cleared ART100 blood circulation systems, following a multi-patient clinical evaluation. The order provides a key reference for ongoing strategic discussions to monetize the ART100 platform and medical assets.
Key Financial Metrics
Key Facts
- $580,000 commercial purchase order from NYU Langone Hospital for ART100 systems
- Order follows successful clinical evaluation in over 30 patients
- NYU Langone is a top-ranked academic medical center; provides strong reference for commercial discussions
- Company is engaged in an active strategic process to potentially monetize the ART100 platform and other medical assets
Financial Impact
$580,000 commercial order for a $17M market cap company; modest but meaningful for a small-cap
Risk Factors
- Order is relatively small ($580k) and may not lead to significant recurring revenue
- Strategic process may not result in favorable monetization outcomes
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3296515 |
Track record
13 reports on IINN
The track record builds as more bullish or bearish reports settle.
Filters
- Oct 9, 20265w ago 6-K Neutral 4/10 No price data
- May 29, 202624w ago Press Release Mixed 5/10 Entry $3.07 to $1.87 ▼ −39.09% −38.80% vs SPY
- May 18, 202626w ago Press Release Bullish 5/10 Viewing Entry $0.3723 to $1.52 ▲ +308.27% +306.65% vs SPY
- May 11, 202627w ago Press Release Neutral 5/10 Entry $0.4070 to $0.3720 ▼ −8.60% −8.51% vs SPY
- May 1, 202628w ago Press Release Neutral 4/10 Entry $0.4680 to $0.4500 ▼ −3.85% −6.19% vs SPY
- Apr 16, 202630w ago Press Release Bullish 6/10 Entry $0.4950 to $0.5400 ▲ +9.09% +8.11% vs SPY
- Apr 14, 202630w ago Press Release Neutral 3/10 Entry $0.4750 to $0.5800 ▲ +22.11% +20.71% vs SPY
- Apr 13, 202631w ago Press Release Mixed 5/10 Entry $0.5080 to $0.5870 ▲ +15.55% +12.26% vs SPY
- Apr 6, 202632w ago Press Release Neutral 4/10 Entry $0.4110 to $0.5080 ▲ +23.60% +19.47% vs SPY
- Apr 6, 202632w ago Press Release Bullish 7/10 Entry $0.4110 to $0.5080 ▲ +23.60% +19.47% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers